phenylalanine has been researched along with Neuroendocrine Tumors in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Markham, A | 1 |
| Masab, M; Saif, MW | 1 |
| Kasi, PM | 1 |
| Beaumont, JL; Cella, D; Feuilly, M; Hörsch, D; Houchard, A; Hudgens, S; Kulke, MH; Lapuerta, P; Marteau, F; Pavel, M; Ramage, J | 1 |
| Benson Iii, AB; Wolin, EM | 1 |
| Castaño, JP; de Herder, WW; Dogan-Oruc, F; Feelders, RA; Herrera-Martínez, AD; Hofland, LJ; Van den Dungen, R; van Koetsveld, PM | 1 |
| Barriuso, J; Hubner, RA; Lamarca, A; McNamara, MG; Valle, JW | 1 |
4 review(s) available for phenylalanine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Topics: Administration, Oral; Diarrhea; Female; Humans; Male; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Phenylalanine; Pyrimidines | 2017 |
Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues.
Topics: Clinical Trials as Topic; Diarrhea; Humans; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Phenylalanine; Pyrimidines; Somatostatin | 2018 |
Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Male; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Phenylalanine; Practice Guidelines as Topic; Prospective Studies; Pyrimidines; Quality of Life; Somatostatin; Treatment Outcome | 2019 |
Telotristat ethyl: a new option for the management of carcinoid syndrome.
Topics: Animals; Carcinoid Tumor; Clinical Trials as Topic; Humans; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Phenylalanine; Pyrimidines; Somatostatin; Tryptophan Hydroxylase | 2016 |
1 trial(s) available for phenylalanine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.
Topics: Aged; Diarrhea; Double-Blind Method; Female; Humans; Male; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Phenylalanine; Pyrimidines; Quality of Life; Treatment Outcome; Tryptophan Hydroxylase | 2018 |
2 other study(ies) available for phenylalanine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Telotristat Ethyl: First Global Approval.
Topics: Animals; Diarrhea; Drug Approval; Drug Therapy, Combination; Humans; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Phenylalanine; Pyrimidines; Randomized Controlled Trials as Topic; Somatostatin; Tryptophan Hydroxylase; United States; United States Food and Drug Administration | 2017 |
Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; In Vitro Techniques; Neuroendocrine Tumors; Pancreatic Neoplasms; Phenylalanine; Pyrimidines; Serotonin; Tryptophan Hydroxylase; Tumor Cells, Cultured | 2020 |